Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
DETAILED ACTION
Applicant’s amendments and remarks filed on July 6, 2026 are acknowledged.
Claims 2-30 and 32-54 have been canceled. Claims 1, 55, 64, and 66 were amended. Claims 1, 31, and 55-68 are pending and are examined on the merits herein.
Priority
PNG
media_image1.png
50
460
media_image1.png
Greyscale
Information Disclosure Statement
The information disclosure statement (IDS) submitted on June 26, 2026 and July 21, 2026 is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statements are being considered by the examiner.
The information disclosure statement filed June 26, 2026 fails to comply with 37 CFR 1.98(a)(2), which requires a legible copy of each cited foreign patent document; each non-patent literature publication or that portion which caused it to be listed; and all other information or that portion which caused it to be listed. A copy of cite no. 1 of the non-patent literature documents section was not submitted; therefore, the reference has been lined through on the IDS.
The information disclosure statement filed June 26, 2026 fails to comply with 37 CFR 1.98(a)(1), which requires the following: (1) a list of all patents, publications, applications, or other information submitted for consideration by the Office; (2) U.S. patents and U.S. patent application publications listed in a section separately from citations of other documents; (3) the application number of the application in which the information disclosure statement is being submitted on each page of the list; (4) a column that provides a blank space next to each document to be considered, for the examiner’s initials; and (5) a heading that clearly indicates that the list is an information disclosure statement. A copy of the following reference was submitted; however, it does not appear that this reference is listed on the IDS. In addition, it is noted that this reference is in a foreign language.
PNG
media_image2.png
42
222
media_image2.png
Greyscale
Withdrawn Objections
In view of Applicant’s amendments and response, the objection to the abstract is withdrawn.
In view of Applicant’s amendments and response, the objection to claim 55 is withdrawn.
Withdrawn Rejections
In view of Applicant’s amendments and response, the 35 U.S.C. 112(d) and 35 U.S.C. 112(a) written description rejections are withdrawn.
Specification
It is noted that the amendment to the specification filed on July 6, 2026 does not comply with the requirements of 37 CFR 1.121(b) because the amendment does not include clear instructions. Therefore, the amendment to the specification has not been entered. Specifically, the instructions do not appear to reference the page and line numbers of the specification filed on September 4, 2025.
The disclosure is objected to because of the following informalities:
In the brief description of the figures section, Figure 1 discloses production of inhibitory RNAs from an exemplary target transcript template designated as SEQ ID NOS: 14-18. However, it is unclear which sequences the SEQ ID NOS. correspond to in the figure.
In the brief description of the figures section, Figures 3 and 4 do not refer to “A” and “B” as in the drawings.
In the brief description of the figures section, Figure 6 discloses APOE knock down of expression by four different siRNAs in vitro (SEQ ID NOS: 1-5); however, it is unclear which sequences the SEQ ID NOS. correspond to in the figure.
Page 39, line 8 reads “(red/bold)”; however, the specification does not contain color.
Appropriate correction is required.
Response to Arguments
Applicant's arguments filed July 6, 2026 have been fully considered but they are not persuasive.
It is noted that the amendment to the specification filed on July 6, 2026 does not comply with the requirements of 37 CFR 1.121(b) because the amendment does not include clear instructions. Therefore, the amendment to the specification has not been entered. Specifically, the instructions do not appear to reference the page and line numbers of the specification filed on September 4, 2025.
Therefore, the Examiner is maintaining the objections to the specification.
Claim Objections
Claims 1 and 64 are objected to because of the following informalities:
Claim 1 recites the abbreviations APOE4 and APOE2. The abbreviation should be clearly written out at their first occurrence in the claim and should be followed by the abbreviation in parentheses.
There are two (2) semicolons in claim 1 after “SEQ ID NO: 25”.
Claim 64 recites in part “claim of 63” and should recite in part “of claim 63”.
Appropriate correction is required.
Response to Arguments
Applicant's arguments filed July 6, 2026 assert that claims 55 and 64 were amended to overcome the objections. In view of Applicant’s amendments and response, the objection to claim 55 is withdrawn. Previous claim 64 was missing the word “of” before “claim 63”; however, claim 64 was amended to recite in part “The AAV vector claim of 63” instead of “The AAV vector of claim 63”.
Claim Rejections - 35 USC § 112
The following is a quotation of the first paragraph of 35 U.S.C. 112(a):
(a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention.
The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112:
The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention.
Enablement
Claim 31 is rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.
There are many factors to be considered when determining whether there is
sufficient evidence to support a determination that a disclosure does not satisfy the
enablement requirement and whether any necessary experimentation is "undue".
These factors include, but are not limited to: (A) The breadth of the claims; (B) The
nature of the invention; (C) The state of the prior art; (D) The level of one of ordinary
skill; (E) The level of predictability in the art; (F) The amount of direction provided by the
inventor; (G) The existence of working examples; and (H) The quantity of
experimentation needed to make or use the invention based on the content of the
disclosure. All of the Wands factors have been considered with regard to the instant claims, with the most relevant factors discussed below.
Breadth of claims:
Claim 31 is drawn to a method to prevent, inhibit, or treat a disease associated with APOE4 expression in a mammal comprising administering to the mammal an effective amount of a composition comprising the AAV vector of claim 1.
The broadest reasonable interpretation of claim 31 is a method to prevent, inhibit, or treat any disease associated with APOE4 expression in a mammal comprising administering to the mammal an effective amount of a composition comprising the AAV vector of claim 1.
Nature of the invention:
The specification filed on September 4, 2025 envisions a method to prevent, inhibit, or treat Alzheimer’s disease in a mammal comprising administering to the mammal an effective amount of a composition comprising the gene therapy vector [page 4, last paragraph]. The specification also envisions a method to prevent, inhibit, or treat a disease associated with APOE4 expression in a mammal comprising administering to the mammal an effective amount of a composition comprising the gene therapy vector [page 5, first full paragraph]. Therefore, the AAV vector must be capable of providing a therapeutic outcome for Alzheimer’s disease or any disease associated with APOE4 expression.
Amount of direction provided by the inventor and existence of working
examples:
The specification discloses that adeno-associated virus (AAV) delivery of the human APOE2 gene to murine models of AD expressing human APOE4 demonstrated reduced amyloid-β peptide and amyloid burden. The specification envisions that suppression of APOE4 via delivery of an AAV vector while simultaneously expressing human APOE2 may reduce the risk for Alzheimer’s disease even further. In one embodiment, gene therapy such as AAV therapy is designed to deliver the human APOE2 gene coding sequence and artificial RNAs such as miRNA targeted to the endogenous APOE4. The combination of knockdown of detrimental endogenous APOE4 expression with the expression of the beneficial APOE2 allele may provide enhanced protection from AD development for individuals with homozygous for the APOE4 allele [page 35, last paragraph bridging to page 36]. In one embodiment, siRNA interacts with mRNA to silence translation. To express an siRNA from a DNA sequence, such as a gene therapy expression vector, the targeting sequence must be embedded in a shRNA or miRNA scaffold [page 36, first full paragraph]. Further, the specification envisions that knockdown with miRNA against all isoforms of endogenous APOE may be accomplished using multiple miRNAs targeting different sections of APOE mRNA thereby enhancing silencing. In one embodiment, the vector-derived human APOE2 may contain silent mutations in the coding sequence to prevent silencing [page 36, second full paragraph]. The specification also envisions that the miRNA having the RNAi sequences to inhibit APOE4 expression may be inserted into 5’ non-coding sequences, e.g., an intron, and/or 3’ non-coding sequences. Multiple miRNAs can be placed in tandem for enhanced silencing of APOE4 [Figure 3; page 36, third full paragraph].
Working example 2 discloses that Figure 6 depicts testing of APOE knockdown efficiency by siRNAs in U87 cells. Four different siRNAs targeting the coding sequence of APOE were generated based on a comparison of multiple siRNA design algorithms. siRNAs were transfected into U87 cells and APOE mRNA copies were quantified by RT-qPCR. The identified sequences were designated as SEQ ID NOS: 1-4, the non-targeting siRNA is SEQ ID NO: 5, and other sequences for siRNAs include SEQ ID NOS: 20-22. Only SEQ ID NO: 2 was converted into a miRNA and a scaffold based on a modified version of miR-155 was employed. For example, for a miR from SEQ ID NO: 2, SEQ ID NOS: 23, 24, or 25 may be employed. On page 38 lines 10-11, the specification envisions that any miRNA backbone may be employed, e.g., miR-21, miR-30, or miR-33.
State of the prior art, level of predictability in the art, and level of one of
ordinary skill:
Lam et al. (Molecular Therapy – Nucleic Acids 2015) discloses that siRNAs and miRNAs have similar physicochemical properties but distinct functions. Both are short RNA duplexes that target mRNA(s) to produce a gene silencing effect, yet their mechanisms of action are distinct. As a result, the requirements for sequence design and therapeutic applications of siRNAs and miRNAs are different. On the other hand, for clinical development, the two types of small RNA molecules face a similar set of barriers: poor stability in vivo, delivery challenges and off-target effects [page 1, right column, first full paragraph].
Although post-filing, Walgrave et al. (Molecular Neurodegeneration 2021) discloses that profiling the impact of miRNA-based multi-targeting therapeutic strategies in Alzheimer’s disease with respect to efficacy and toxicity remains a daunting task, which is reflected by the current sparsity of miRNA therapeutics undergoing clinical trials in AD [page 2, left column, first full paragraph]. Walgrave et al. also discloses that further basic research first, to better characterize how miRNAs target pathways of interest, and second, to systematically map on- and off target toxic effects, is a prerequisite for effective clinical application in AD and other neurodegenerative disorders [page 10, left column, second full paragraph].
Graham et al. (Annual Review of Medicine 2017) discloses that Alzheimer’s disease (AD) is the primary cause of age-related dementia. Effective strategies to prevent and treat AD remain elusive despite major efforts to understand its basic biology and clinical pathophysiology [abstract].
Galvin (Journal of the American Geriatrics Society 2017) discloses that ongoing pharmacological trials using anti-amyloid therapies are underway in sporadic and genetic forms of AD, although a large number of modifiable risk factors for AD have been identified in observational studies, many of which do not appear to exert effects through amyloid or tau. Thus suggesting that prevention studies focusing on risk reduction and lifestyle modification may offer additional benefits [abstract]. Galvin further discloses that an important question is whether AD can be prevented and identified a number of modifiable (e.g., exposures, lifestyle and social habits) and nonmodifiable (e.g., age, sex, genetics) risk factors [page 2128, right column]. A number of prevention studies are ongoing in sporadic and autosomal-dominant forms of AD; however, the results are still pending. Nonetheless, the results from the trials may not be generalizable [page 2129, left column, last paragraph bridging to right column, first paragraph]. Furthermore, Galvin discloses that up to 30% of AD cases may be preventable through modification of risk factors and behavioral changes to mitigate the effect of those risk factors that are not modifiable. A prevention initiative needs to be multimodal and tailored to address individual risks [page 2130, left column, last full paragraph].
Although post-filing, Vitek et al. (Translational Research & Clinical Interventions 2020; reference cited by Applicant) discloses that models reflecting only single aspects of Alzheimer’s disease (AD) pathogenesis do not mimic AD [abstract]. Existing AD animal models have provided important insights into the disease; however, the inability of these models to reflect the entire biology of the disease, much less predict efficacy in clinical trials, has contributed to the high failure rate (99.6%) of AD drugs in clinical development [page 2, left column, second paragraph]. Vitek et al. also discloses that most of the AD mice do not develop neurodegeneration, the models are focused largely on familial AD (FAD) with early onset AD (EOAD) mechanisms, the genetic backgrounds of the mouse strains have not been standardized, and the models incompletely recapitulate the human neuropathology phenotype of typical late-onset Alzheimer’s dementia (LOAD) thus limiting the translatability of findings from transgenic mouse strain to the human disease condition. Further, other limitations of mouse models are expected as a result of their smaller and less-developed prefrontal cortex and a shorter lifespan that may not be useful in studying age-related neurodegenerative diseases such as AD. In addition, there are substantial differences between mouse and human immune systems [page 2, right column, first paragraph]. Vitek et al. also discloses that since no model accurately recapitulates all aspects of AD, a strategically-driven multi-model evaluation strategy incorporating both genetic models and currently available “agnostic” aged animal models of AD-like progression should be considered for drug development to de-risk the transition of pre-clinical drug assets to the clinic [page 9, right column, first full paragraph].
Quantity of experimentation:
In view of the breadth of the claims which embrace an AAV vector that must be capable of providing a therapeutic outcome for Alzheimer’s disease or any disease associated with APOE4 expression, the lack of working examples to show any other sequence besides SEQ ID NO: 2 encoding any other APOE4-targeting miRNA besides miR-155, and the failure to provide adequate guidance to overcome the state and level of predictability of the art, one of skill would have to perform undue experimentation in order to practice the invention commensurate in scope with the claims.
Response to Arguments
Applicant's arguments filed July 6, 2026 have been fully considered but they are not persuasive.
Applicant asserts that amending claim 1 overcomes the 35 U.S.C. 112(a) enablement rejection.
This argument is not found persuasive. As discussed in the original 35 U.S.C. 112(a) enablement rejection, in view of the breadth of the claims which embrace an AAV vector that must be capable of providing a therapeutic outcome for Alzheimer’s disease or any disease associated with APOE4 expression, the lack of working examples to show any other sequence besides SEQ ID NO: 2 encoding any other APOE4-targeting miRNA besides miR-155, and the failure to provide adequate guidance to overcome the state and level of predictability of the art, one of skill would have to perform undue experimentation in order to practice the invention commensurate in scope with the claims. Therefore, the Examiner is maintaining the 35 U.S.C. 112(a) enablement rejection.
Conclusion
Claims 55-63 and 65-68 are allowed.
THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).
A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to CHRISTINA TRAN whose telephone number is (571)270-0550. The examiner can normally be reached M-F 7:30 - 5:00pm.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jennifer Dunston can be reached at (571) 272-2916. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/C.T./
Examiner, Art Unit 1637
/Jennifer Dunston/Supervisory Patent Examiner, Art Unit 1637
Prosecution Insights